Han-Joon Kim1, Beom S Jeon, Jee-Young Lee, Ji Young Yun. 1. Departments of Neurology and Movement Disorder Center and Neuroscience Research Institute, BK21, College of Medicine, Seoul National University, Seoul, Korea.
Abstract
METHODS: We conducted a retrospective medical record review to determine the survival of 455 Korean multiple system atrophy (MSA) patients and examined the effect of clinical factors that could possibly influence survival. The patients comprised 222 men and 233 women. RESULTS: Age at onset was 60.1 ± 8.8 years (mean ± SD) and did not differ between the sexes. Parkinsonism was the most prevalent initial symptom, followed by cerebellar dysfunction and dysautonomia. Age at onset was significantly older in patients with predominant parkinsonism at the last visit (MSA-P) than in the other patients. At the time of data collection, 107 patients had died. Median survival time was 10 years. The survival rate of women was slightly better than that of men, especially in MSA-P patients. CONCLUSIONS: Survival was not affected by age at onset, initial symptom, or predominant symptom at the last visit or by the presence of autonomic symptoms or multiple symptoms at disease onset.
METHODS: We conducted a retrospective medical record review to determine the survival of 455 Korean multiple system atrophy (MSA) patients and examined the effect of clinical factors that could possibly influence survival. The patients comprised 222 men and 233 women. RESULTS: Age at onset was 60.1 ± 8.8 years (mean ± SD) and did not differ between the sexes. Parkinsonism was the most prevalent initial symptom, followed by cerebellar dysfunction and dysautonomia. Age at onset was significantly older in patients with predominant parkinsonism at the last visit (MSA-P) than in the other patients. At the time of data collection, 107 patients had died. Median survival time was 10 years. The survival rate of women was slightly better than that of men, especially in MSA-Ppatients. CONCLUSIONS: Survival was not affected by age at onset, initial symptom, or predominant symptom at the last visit or by the presence of autonomic symptoms or multiple symptoms at disease onset.
Authors: Elizabeth A Coon; Renee M Nelson; David M Sletten; Mariana D Suarez; J Eric Ahlskog; Eduardo E Benarroch; Paola Sandroni; Jay N Mandrekar; Phillip A Low; Wolfgang Singer Journal: Auton Neurosci Date: 2019-04-24 Impact factor: 3.145
Authors: Juan J Figueroa; Wolfgang Singer; Ajay Parsaik; Eduardo E Benarroch; J Eric Ahlskog; Robert D Fealey; Joseph E Parisi; Paola Sandroni; Jay Mandrekar; Valeria Iodice; Phillip A Low; James H Bower Journal: Mov Disord Date: 2014-06-07 Impact factor: 10.338
Authors: Elizabeth A Coon; David M Sletten; Mariana D Suarez; Jay N Mandrekar; J Eric Ahlskog; James H Bower; Joseph Y Matsumoto; Michael H Silber; Eduardo E Benarroch; Robert D Fealey; Paola Sandroni; Phillip A Low; Wolfgang Singer Journal: Brain Date: 2015-09-13 Impact factor: 13.501
Authors: F Krismer; S Duerr; M Minnerop; T Klockgether; M Stamelou; K M Eggert; W H Oertel; A Schrag; W Poewe; G K Wenning Journal: Nervenarzt Date: 2013-06 Impact factor: 1.214